Supernus Pharmaceuticals, Inc. (SUPN)
Largest Insider Buys in Sector
SUPN Stock Price History Chart
SUPN Stock Performance
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The …
Insider Activity of Supernus Pharmaceuticals, Inc.
Over the last 12 months, insiders at Supernus Pharmaceuticals, Inc. have bought $0 and sold $4.24M worth of Supernus Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Supernus Pharmaceuticals, Inc. have bought $0 and sold $4.2M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 14,400 shares for transaction amount of $379,964 was made by Khattar Jack A. (President, CEO) on 2019‑08‑23.
List of Insider Buy and Sell Transactions, Supernus Pharmaceuticals, Inc.
| 2024-09-13 | Sale | director | 10,000 0.0183% | $31.33 | $313,300 | +3.73% | ||
| 2024-03-21 | Sale | Sr. VP of IP, CSO | 14,491 0.0266% | $35.31 | $511,677 | -11.84% | ||
| 2024-03-20 | Sale | Sr. VP of IP, CSO | 400 0.0007% | $35.31 | $14,124 | -10.81% | ||
| 2024-03-19 | Sale | Sr. VP of IP, CSO | 12,364 0.0227% | $35.31 | $436,573 | -11.44% | ||
| 2024-03-13 | Sale | Sr. VP of IP, CSO | 62,366 0.1107% | $33.74 | $2.1M | -9.89% | ||
| 2024-03-12 | Sale | Sr. VP of IP, CSO | 3,884 0.0071% | $32.99 | $128,133 | -4.89% | ||
| 2024-02-26 | Sale | Sr. VP of IP, CSO | 5,000 0.0094% | $30.21 | $151,050 | +5.47% | ||
| 2024-01-10 | Sale | Sr. V.P., Regulatory Affairs | 8,000 0.0146% | $27.91 | $223,280 | +8.86% | ||
| 2023-11-16 | Sale | director | 2,500 0.0046% | $28.01 | $70,025 | +5.85% | ||
| 2023-11-15 | Sale | director | 9,093 0.0166% | $28.50 | $259,151 | +3.53% | ||
| 2023-11-14 | Sale | SVP, Quality, GMP, Ops, IT | 1,110 0.002% | $28.13 | $31,224 | +4.51% | ||
| 2023-08-30 | Sale | Sr. V.P., Regulatory Affairs | 8,100 0.0149% | $32.00 | $259,200 | -11.39% | ||
| 2023-08-25 | Sale | Sr. V.P., Regulatory Affairs | 5,135 0.0095% | $31.59 | $162,215 | -9.81% | ||
| 2023-03-14 | Sale | Sr VP, Quality, GMP Oper. & IT | 4,780 0.0087% | $35.99 | $172,023 | -17.41% | ||
| 2023-02-03 | Sale | President, CEO | 200 0.0004% | $42.02 | $8,404 | -26.44% | ||
| 2023-02-02 | Sale | President, CEO | 13,532 0.0249% | $42.05 | $569,088 | -27.12% | ||
| 2023-02-01 | Sale | President, CEO | 300 0.0006% | $42.01 | $12,602 | -26.24% | ||
| 2023-01-31 | Sale | President, CEO | 976 0.0018% | $42.01 | $41,002 | -25.14% | ||
| 2023-01-18 | Sale | President, CEO | 4,936 0.0091% | $40.40 | $199,394 | -21.48% | ||
| 2023-01-17 | Sale | President, CEO | 25,446 0.0467% | $40.03 | $1.02M | -21.01% |
Insider Historical Profitability
| NEWHALL CHARLES W III | director | 117089 0.2125% | $37.98 | 1 | 1 | +29.48% |
| Martin Tami Tillotson | Sr. V.P., Regulatory Affairs | 85664 0.1555% | $37.98 | 1 | 7 | +29.48% |
| Hudson Frederick M. | director | 33231 0.0603% | $37.98 | 1 | 2 | +29.48% |
| NEW ENTERPRISE ASSOCIATES 11 LP | 10 percent owner | 10641250 19.3107% | $37.98 | 1 | 0 | +29.48% |
| Abingworth Management LTD | 10 percent owner | 3600000 6.5329% | $37.98 | 1 | 0 | +29.48% |
Institutional Investor Ownership
| BlackRock | $353.46M | 18.85 | 10.36M | -0.2% | -$696,321.54 | 0.01 | |
| The Vanguard Group | $211.71M | 11.29 | 6.21M | -0.13% | -$270,048.87 | <0.01 | |
| Armistice Capital Llc | $121.84M | 6.5 | 3.57M | -23.18% | -$36.77M | 0.39 | |
| Macquarie Group | $91.04M | 4.86 | 2.67M | -2.51% | -$2.34M | 0.08 | |
| Dimensional Fund Advisors | $87.22M | 4.65 | 2.56M | +4.09% | +$3.43M | 0.02 |